Primary Central Nervous System Lymphomas in Immunocompetent Individuals: Histology, Epstein-Barr Virus Genome, Ki-67 Proliferation Index, p53 and bcl-2 Gene Expression

References

• Ferreri A. J. M., Reni M., Villa E. Primary central nervous system lymphomas in immunocompetent patients. Cancer Treat. Rev. 1995; 21: 415–446
   PubMed Web of Science ®Google Scholar
• Jellinger K. A., Paulus W. Primary central nervous system lymphomas—an update. J. Cancer Res. Clin. Oncol. 1992; 119: 7–27
   PubMed Web of Science ®Google Scholar
• Ling S. M., Roach M., III, Larson D. A., Wara W. M. Radiotherapy of primary central nervous system lymphomas in patients with and without human immunodeficiency virus. Cancer 1994; 73: 2570–2582
   PubMed Web of Science ®Google Scholar
• Eby N. L., Grufferman S., Flannelly C. M., Schold S. C., Vogel F. S., Burger P. C. Increasing incidence of primary brain lymphoma in the US. Cancer 1988; 62: 2461–2465
   PubMed Web of Science ®Google Scholar
• Krogh-Jensen M., D'Amore F., Jensen M. K., Christensen B. E., Thorling K., Pedersen M., Johansen P., Boesen A. M., Andersen E. Clinicopathologic features, survival and prognostic factors of primary central nervous system lymphomas: Trends in incidence of primary central nervous system lymphomas and primary malignant tumors in a well-defined geographical area. Leuk. Lymphoma 1995; 19: 223–233
   PubMed Web of Science ®Google Scholar
• Bessel E. M., Graus F., Punt J. A. G., Firth J. L., Hope D. T., Moloney A. J., Lopez-Guillermo A., Villa S. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J. Clin. Oncol 1996; 14: 945–954
   PubMed Web of Science ®Google Scholar
• Pollack I. F., Lunsford L. D., Flickinger J. C., Dameshek H. L. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphomas. Cancer 1989; 63: 939–947
   PubMed Web of Science ®Google Scholar
• Auperin I., Mikol J., Oksenhendler E., Thiebaut J. B., Brunei M., Dupont B., Morinet F. Primary central nervous system malignant non-Hodgkin's lymphomas from HIV-infected and non-infected patients: expression of cellular surface proteins and Epstein-Barr viral markers. Neuropathol. Appl. Neurobiol. 1994; 20: 243–252
   PubMed Web of Science ®Google Scholar
• Chang K. L., Flaris N., Hickey W. F., Johnson R. M., Meyer J. S., Weiss L. M. Brain lymphomas of immunocompetent and immunocompromised patients: Study of the association with Epstein-Barr virus. Modern Pathol. 1993; 6: 427–432
   PubMed Web of Science ®Google Scholar
• Deangelis L. M., Wong E., Rosenblum M., Furneaux H. Epstein-Barr virus in the acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma. Cancer 1992; 70: 1607–1611
   PubMed Web of Science ®Google Scholar
• Geddes J. F., Bhattacharjee M. B., Savage K., Scaravilli F., McLaughlin J. E. Primary cerebral lymphoma: A study of 47 cases probed for Epstein-Barr virus genome. J. Clin. Pathol. 1992; 45: 587–590
   PubMed Web of Science ®Google Scholar
• Hamilton-Dutoit S. J., Raphael M., Audouin J., Diebold J., Lisse I., Pedersen C., Oksenhendler E., Marelle L., Pallesen G. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrom-related lymphomas: Correlation with tumor morphology and primary site. Blood 1993; 82: 619–624
   PubMed Web of Science ®Google Scholar
• Ironside J. W. Epstein-Barr virus gene expression in CNS lymphomas. Clin. Neuropathol. 1992; 11: 210, abstr).
   Google Scholar
• Murphy J. K., Young L. S., Bevan I. S., Lewis F. A., Dockey D., Ironside J. W., O'Brien C. J., Wells M. Demonstration of Epstein-Barr virus in primary brain lymphoma by in situ DNA hybridisation in paraffin wax embedded tissue. J. Clin. Pathol. 1990; 43: 220–223
   PubMed Web of Science ®Google Scholar
• Rouah E., Rogers B. B., Wilson D. R., Kirkpatrick J. B., Buffone G. J. Demonstration of Epstein-Barr virus in primary central nervous system lymphomas by the polymerase chain reaction and in situ hybridization. Hum. Pathol. 1990; 21: 545–550
   PubMed Web of Science ®Google Scholar
• D'amore F., Christensen B. E., Brincker H., Pedersen N. T., Thorling K., Hastrup J., Pedersen M., Jensen M. K., Johansen P., Andersen E., Bach B., SØRensen E. Clincopathologic features and prognostic factors in extranodal non-Hodgkin lymphomas. Eur. J. Cancer 1991; 27: 1201–1208
   PubMed Web of Science ®Google Scholar
• D'Amore F., Johansen P., Houmand A., Weisenburger D. D., Mortensen L. S. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: Highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood 1996; 87: 1045–1055
   PubMed Web of Science ®Google Scholar
• Glickman J. N., Howe J. G., Steitz J. A. Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells. J. Virol. 1988; 62: 902–911
   PubMed Web of Science ®Google Scholar
• Gilligan K., Rajadurai P., Resnick L., Raab-Traub N. Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS associated leucoplakia. Proc. Natl. Acad. Sci. USA. 1990; 87: 8790–8794
   PubMed Web of Science ®Google Scholar
• Knutson G., Spaulding D. β-actin as a positive control for detection of mRNA by in situ hybridization (ISH). Modern Pathol. 1995; 8: 166A
   Google Scholar
• Craig F. E., Gulley M. L., Banks P. M. Posttransplantation lymphoproliferative disorders. Am. J. Clin. Pathol. 1993; 99: 265–276
   PubMed Web of Science ®Google Scholar
• Karp J. E., Broder S. The pathogenesis of AIDS lymphoma: a foundation for addressing the challenges of therapy and prevention. Leuk. Lymphoma 1992; 8: 167–188
   PubMed Web of Science ®Google Scholar
• Sander C. A., Medeiros L. J., Weiss L. M., Yano T., Sneller M. C., Jaffe E. S. Lymphoproliferative lesions in patients with common variable immunodeficiency syndrome. Am. J. Surg. Pathol. 1992; 16: 1170–1182
   PubMed Web of Science ®Google Scholar
• Weiss L. M., Jaffe E., Liu X-F., Chen Y-Y., Shibata D., Medeiros L. J. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992; 79: 1789–1795
   PubMed Web of Science ®Google Scholar
• Szekely L., Selivanova G., Magnusson K. P., Klein G., Wiman K. G. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA 1993; 90: 5455–5459
   PubMed Web of Science ®Google Scholar
• Henderson S., Rowe M., Gregory C., Croom-Carter D., Wang F., Longnecker R., Kieff E., Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B-cells from programmed cell death. Cell 1991; 65: 1107–1115
   PubMed Web of Science ®Google Scholar
• Shiramizu B., Barriga F., Neequaye J., Jafri A., Della-Favera R., Neri A., Guttierez M., Levine P., Magrath I. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: Relevance to geography and Epstein-Barr virus association. Blood 1991; 77: 1516–1526
   PubMed Web of Science ®Google Scholar
• Gilligan K., Rajadurai P., Resnick L., Raab-Traub N. Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc. Natl. Acad. Sci. USA 1990; 87: 8790–8794
   PubMed Web of Science ®Google Scholar
• Niedobitek G., Herbst H., Young L. S., Brooks L., Masucci M. G., Crocker J., Rickinson A. B., Stein H. Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood 1992; 79: 2520–2526
   PubMed Web of Science ®Google Scholar
• Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N. Eng. J. Med. 1993; 329: 1318–1327
   PubMed Web of Science ®Google Scholar
• Piris M. A., Villuendas R., Martinez J. C. p53 expression in non-Hodgkin's lymphomas: A marker of p53 inactivation?. Leuk. Lymphoma 1995; 17: 35–42
   PubMed Web of Science ®Google Scholar
• Orazi A., Cattoretti G., Heerema N. A., Sozzi G., John K., Neiman R. S. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: An immunohistochemical study of bone marrow biopsies. Modem Pathol. 1993; 6: 521–525
   PubMed Web of Science ®Google Scholar
• Rouby S. E., Thomas A., Costin D., Rosenberg C. R., Potmesil M., Silber R., Newcomb E. W. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459
   PubMed Web of Science ®Google Scholar
• Pins M. A., Pezella F., Martinez-Montero J. C. p53 and bcl-2 expression in high-grade B-cell lyraphomas: correlation with survival time. Br. J. Cancer 1994; 69: 337–341
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P., Oates J., Kittas C., Crocker J. p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphoma. J. Clin. Pathol. 1994; 47: 9–14
   PubMed Web of Science ®Google Scholar
• Soini Y., PÄÄKkÖ P., Alavaikko M., VÄHÄKangas M. p53 expression in lymphatic malignancies. J. Clin. Pathol. 1992; 45: 1011–1014
   PubMed Web of Science ®Google Scholar
• Kramer M. H. H., Hermans J., Parker J., Krol A. D. G., Kluin-Nelemans J. C., Haak H. L., Van Groningen K., Van Krieken J. H. J. M., De Jong D., Kluin P. M. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J. Clin. Oncol. 1996; 14: 2131–2138
   PubMed Web of Science ®Google Scholar
• Wilson W. H., Teruya-Feldstein J., Fest T., Harris C., Steinberg S. M., Jaffe E. S., Raffeld M. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89: 601–609
   PubMed Web of Science ®Google Scholar
• Hockenbery D. M. The bcl-2 oncogene and apoptosis. Semin. Immunol. 1992; 4: 413–420
   PubMedGoogle Scholar
• Gulley M. L., Dent G. A., Ross D. W. Classification and staging of lymphoma by molecular genetics. Cancer 1992; 69: 1600–1606
   PubMed Web of Science ®Google Scholar
• Camilleri-broët S., Davi F., Feuillard J., Bourgeois C., Seilhean D., Hauw J-J., Raphael M. High expression of latent membrane protein 1 of Epstein-Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas. Blood 1995; 86: 432–435
   PubMed Web of Science ®Google Scholar
• Hermine O., Haioun C., Lepage E., D'Agay M. F., Briere J., Lavignac C., Fillet G., Salles G., Marolleau J. P., Diebold J., Reyas F., Gaulard P. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphomas. Blood 1996; 87: 265–272
   PubMed Web of Science ®Google Scholar
• Tang S. C., Visser L., Hepperle B., Hanson J., Poppema S. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large cell non-Hodgkin's lymphomas: An analysis of 83 cases. J. Clin. Oncol 1994; 12: 149–154
   PubMed Web of Science ®Google Scholar
• Hall P. A., Richards M. A., Gregory W. M., D'Ardenne A. J., Lister T. A., Stansfeld A. G. The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphoma. J. Pathol. 1988; 154: 223–235
   PubMed Web of Science ®Google Scholar